ReviewReumatologia2016
Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach.
Review in Reumatologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Role of Cardiac Imaging in the Evaluation of Rheumatoid Arthiritis: A Systematic Analysis.Cureus · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis.Clinical rheumatology · 2025Article
- Analysis of risk factors and the predictive value of a nomogram model for coronary heart disease in patients with rheumatoid arthritis.Frontiers in cardiovascular medicine · 2025Article
- Cardiovascular Risk in Rheumatoid Arthritis: Considerations on Assessment and Management.Mediterranean journal of rheumatology · 2024Review
- Cardiovascular disease risk assessment in patients with rheumatoid arthritis: A scoping review.Clinical rheumatology · 2024Article
- Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care.Clinical and experimental medicine · 2024Review
- Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients.Biomedicines · 2022Article
- Psoriasis and Cardiovascular Risk: A Comprehensive Review.Advances in therapy · 2020Review
- A Special Report on Changing Trends in Preventive Stroke/Cardiovascular Risk Assessment Via B-Mode Ultrasonography.Current atherosclerosis reports · 2019Review
- Rheumatoid Arthritis: Atherosclerosis Imaging and Cardiovascular Risk Assessment Using Machine and Deep Learning-Based Tissue Characterization.Current atherosclerosis reports · 2019Review
- The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.Current atherosclerosis reports · 2017Review
- The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.Mediators of inflammation · 2017Review
- Should all patients with psoriasis receive statins? Analysis according to different strategies.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current methods of cardiovascular (CV) risk assessment in the course of inflammatory connective tissue diseases are a subject of considerable controversy. Comparing different methods of CV risk assessment in current rheumatoid arthritis (RA) guidelines, only a few of them recommend the use of formal risk calculators. These are the EULAR guidelines suggesting the use of SCORE and the British Society for Rheumatology guidelines performed in collaboration with NICE preferring the use of QRISK-2. Analyzing the latest American and British reports, two main concepts could be identified. The first one is to focus on risk calculators developed for the general population taking into account RA, and the calculator that might fulfill this role is the new QRISK-2 presented by NICE in 2014. The second concept is to create RA-specific risk calculators, such as the Expanded Cardiovascular Risk Prediction Score for RA. In this review we also discuss the efficiency of a new Pooled Cohort Equation and other calculators in the general and RA population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.